Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMVE3TK)

Drug Name
Bromocriptine Drug Info
Synonyms
Bagren; Bromergocryptine; Bromocriptin; Bromocriptina; Bromocriptinum; Bromocryptin; Bromocryptine; Bromoergocriptine; Bromoergocryptine; Ergoset; Parlodel; Bromocriptine [BAN]; Bromocriptine methanesulfonate; Parlodel Snaptabs; Alti-Bromocriptine; Apo-Bromocriptine; Bromocriptina [INN-Spanish]; Bromocriptinum [INN-Latin]; CB-154; Parlodel (TN); Bromocriptine (USAN/INN); Bromocriptine [USAN:BAN:INN]; Ergocryptine, 2-bromo-(8CI); (5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-3',6',18-trioxoergotaman; (5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione; (5'alpha)-2-bromo-12'-hydroxy-5'-(2-methylpropyl)-2'-(propan-2-yl)-3',6',18-trioxoergotaman; (5'alpha)-2-bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman; (6aR,9R)-5-Bromo-N-((2R,5S,10aS,10bS)-10b-hydroxy-5-isobutyl-2-isopropyl-3,6-dioxooctahydro-2H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide; 2-Bromo-12'-hydroxy-2'-(1-methylethyl)-5'-alpha-(2-methylpropyl)ergotamin-3',6',18-trione; 2-Bromo-alpha-ergocryptine; 2-Bromo-alpha-ergokryptin; 2-Bromo-alpha-ergokryptine; 2-Bromoergocryptine Methanesulfonate; 2-Bromoergokryptine
Indication
Disease Entry ICD 11 Status REF
Acromegaly 5A60.0 Approved [1]
Hyperprolactinaemia 5A60.1 Approved [1]
Parkinson disease 8A00.0 Approved [2]
Postencephalitic Parkinson disease Approved [1]
Therapeutic Class
Antiparkinson Agents
Cross-matching ID
PubChem CID
31101
ChEBI ID
CHEMBL493
CAS Number
CAS 25614-03-3
TTD Drug ID
DMVE3TK
VARIDT Drug ID
DR00550
INTEDE Drug ID
DR0233
ACDINA Drug ID
D00079

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DTP
DME
DOT
Drug Status:
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Dopamine D2 receptor (D2R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [9]
Haloperidol DM96SE0 Delirium Approved [10]
Perphenazine DMA4MRX Schizophrenia 6A20 Approved [11]
Perazine DM2AOTZ Psychotic disorder 6A20-6A25 Approved [12]
Domperidone DMBDPY0 Gastrointestinal disease DE2Z Approved [13]
Levodopa DMN3E57 Parkinson disease 8A00.0 Approved [14]
Quetiapine DM1N62C Anorexia nervosa cachexia 6B80 Approved [15]
Pimozide DMW83TP Schizophrenia 6A20 Approved [16]
Chlorpromazine DMBGZI3 Acute intermittent hepatic porphyria 5C58.11 Approved [17]
Iloperidone DM6AUFY Schizophrenia 6A20 Approved [18]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By P-glycoprotein 1 (ABCB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Amoxicillin DMUYNEI Acute otitis media AB00 Approved [19]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [20]
Methotrexate DM2TEOL Anterior urethra cancer Approved [21]
Folic Acid DMEMBJC Colorectal carcinoma Approved [22]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [21]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [21]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [23]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [21]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [24]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [25]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [26]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [27]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [28]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [29]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [30]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [31]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [32]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [33]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [27]
Verapamil DMA7PEW Angina pectoris BA40 Approved [34]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By D(2) dopamine receptor (DRD2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Droperidol DM0DXA8 Nausea MD90 Approved [35]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [35]
Zuclopenthixol DMKYD5N Schizophrenia 6A20 Approved [35]
Meglitinides DM1OFHN Type-2 diabetes 5A11 Approved [36]
Sulpiride DMF54ZG Schizophrenia 6A20 Approved [37]
Risperidone DMN6DXL Bipolar I disorder Approved [38]
Olanzapine DMPFN6Y Bipolar depression Approved [39]
Methamphetamine DMPM4SK Anxiety Approved [40]
Fluphenazine DMIT8LX Psychotic disorder 6A20-6A25 Approved [41]
Chlorpromazine DMBGZI3 Acute intermittent hepatic porphyria 5C58.11 Approved [42]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Pro-opiomelanocortin (POMC)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Citalopram DM2G9AE Acute coronary syndrome BA41 Approved [43]
Prednisone DM2HG4X Acute asthma CA23 Approved [44]
Naloxone DM3FXMA Narcotic depression 6A7Z Approved [45]
Clonidine DM6RZ9Q Attention deficit hyperactivity disorder 6A05.Z Approved [46]
Fentanyl DM8WAHT Analgesia MB40.8 Approved [47]
Cyproheptadine DM92AH3 Allergic rhinitis CA08.0 Approved [48]
Triamcinolone DM98IXF Acute adrenal insufficiency Approved [49]
Buspirone DMBS632 Anxiety disorder 6B00-6B0Z Approved [50]
Ethanol DMDRQZU Chronic pain MG30 Approved [51]
Metyrapone DMI7FVQ Cushing disease 5A70 Approved [52]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Follitropin subunit beta (FSHB)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Crizotinib DM4F29C Non-small-cell lung cancer 2C25.Y Approved [53]
Cyclophosphamide DM4O2Z7 Advanced cancer 2A00-2F9Z Approved [54]
Goserelin DMAT8CG Breast cancer 2C60-2C65 Approved [55]
Folic Acid DMEMBJC Colorectal carcinoma Approved [56]
Cetrorelix DMFD9Q6 Ovarian stimulation LB45.1 Approved [57]
Letrozole DMH07Y3 Estrogen-receptor positive breast cancer Approved [58]
Cimetidine DMH61ZB Acid-reflux disorder DA22 Approved [59]
Risperidone DMN6DXL Bipolar I disorder Approved [60]
Ethinyl Estradiol DMODJ40 Acne vulgaris ED80 Approved [61]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [62]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Lutropin subunit beta (LHB)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Leuprorelin acetate DM15HAT Prostate cancer 2C82.0 Approved [63]
Levonorgestrel DM1DP7T Atypical endometrial hyperplasia Approved [64]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [65]
Naloxone DM3FXMA Narcotic depression 6A7Z Approved [66]
Crizotinib DM4F29C Non-small-cell lung cancer 2C25.Y Approved [53]
Alprazolam DMC7XDN Anxiety Approved [67]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [68]
Norethindrone acetate DMDGCQP N. A. N. A. Approved [64]
Metoclopramide DMFA5MY Nausea MD90 Approved [66]
Cetrorelix DMFD9Q6 Ovarian stimulation LB45.1 Approved [57]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Agonist [3]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [4]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) Main DME DE4LYSA CP3A4_HUMAN Substrate [5]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
D(2) dopamine receptor (DRD2) OTBLXKEG DRD2_HUMAN Drug Response [6]
Follitropin subunit beta (FSHB) OTGLS283 FSHB_HUMAN Gene/Protein Processing [7]
Lutropin subunit beta (LHB) OT5GBOVJ LSHB_HUMAN Gene/Protein Processing [7]
Pro-opiomelanocortin (POMC) OTV41F7T COLI_HUMAN Gene/Protein Processing [8]

References

1 Bromocriptine FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 35).
3 Silymarin BIO-C, an extract from Silybum marianum fruits, induces hyperprolactinemia in intact female rats. Phytomedicine. 2009 Sep;16(9):839-44.
4 Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
5 Kinetics of dithionite-dependent reduction of cytochrome P450 3A4: heterogeneity of the enzyme caused by its oligomerization. Biochemistry. 2005 Oct 25;44(42):13902-13.
6 Imaging gene-substance interactions: the effect of the DRD2 TaqIA polymorphism and the dopamine agonist bromocriptine on the brain activation during the anticipation of reward. Neurosci Lett. 2006 Sep 25;405(3):196-201. doi: 10.1016/j.neulet.2006.07.030. Epub 2006 Aug 8.
7 Resolution of hyperprolactinaemia after bromocriptine-induced pregnancy. Lancet. 1979 Apr 7;1(8119):784-5. doi: 10.1016/s0140-6736(79)91247-9.
8 Bromocriptine inhibits pro-opiomelanocortin mRNA and ACTH precursor secretion in small cell lung cancer cell lines. J Clin Invest. 1992 Sep;90(3):705-10. doi: 10.1172/JCI115941.
9 The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
10 Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
11 CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
12 Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
13 Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
14 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
15 Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
16 [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
17 Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
18 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
19 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
20 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
21 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
22 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
23 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
24 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
25 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
26 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
27 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
28 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
29 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
30 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
31 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
32 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
33 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
34 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
35 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
36 Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. Psychopharmacology (Berl). 2008 Apr;197(2):229-35. doi: 10.1007/s00213-007-1029-z. Epub 2007 Dec 6.
37 Positron emission tomography measurement of dopamine D? receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia. J Clin Psychiatry. 2010 Sep;71(9):1131-7. doi: 10.4088/JCP.08m04307yel. Epub 2010 Feb 23.
38 Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenet Genomics. 2009 May;19(5):373-82. doi: 10.1097/FPC.0b013e328329a60f.
39 Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment. Pharmacogenet Genomics. 2010 Jun;20(6):359-66. doi: 10.1097/FPC.0b013e3283397d06.
40 A preliminary study: novelty seeking, frontal executive function, and dopamine receptor (D2) TaqI A gene polymorphism in patients with methamphetamine dependence. Compr Psychiatry. 2008 Jul-Aug;49(4):387-92. doi: 10.1016/j.comppsych.2008.01.008. Epub 2008 Mar 21.
41 Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs. Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):11927-32. doi: 10.1073/pnas.0609752104. Epub 2007 Jul 2.
42 Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients. Neurosci Lett. 2005 Mar 7;376(1):1-4. doi: 10.1016/j.neulet.2004.11.014. Epub 2004 Dec 2.
43 Neuroendocrine effects of citalopram, a selective serotonin re-uptake inhibitor, during lifespan in humans. J Endocrinol Invest. 2010 Oct;33(9):657-62. doi: 10.1007/BF03346666. Epub 2010 Apr 22.
44 Prednisone effects on neurochemistry and behavior. Preliminary findings. Arch Gen Psychiatry. 1990 Oct;47(10):963-8. doi: 10.1001/archpsyc.1990.01810220079010.
45 Endogenous opioids modulate the cardiovascular response to mental stress. Psychoneuroendocrinology. 1990;15(3):185-92. doi: 10.1016/0306-4530(90)90029-9.
46 Normalization of blood pressure and plasma concentrations of beta-endorphin and leucine-enkephalin in patients with primary hypertension after treatment with clonidine. J Cardiovasc Pharmacol. 1987;10 Suppl 12:S147-51.
47 Serum beta-endorphin response to stress before and after operation under fentanyl anesthesia in neonates, infants and preschool children. Eur J Pediatr Surg. 2010 Mar;20(2):106-10. doi: 10.1055/s-0029-1243620. Epub 2010 Jan 18.
48 [Toxicity of cyproheptadine. Side effects and accidental overdosage (author's transl)]. Monatsschr Kinderheilkd (1902). 1978 Mar;126(3):123-6.
49 Steroid myopathy induced by epidural triamcinolone injection. Br J Rheumatol. 1995 Apr;34(4):385-6. doi: 10.1093/rheumatology/34.4.385.
50 Hormonal responses to the 5-HT1A agonist buspirone in remitted endogenous depressive patients after long-term imipramine treatment. Psychoneuroendocrinology. 2010 May;35(4):481-9. doi: 10.1016/j.psyneuen.2009.08.012. Epub 2009 Sep 16.
51 The role of acetaldehyde in mediating effects of alcohol on expression of endogenous opioid system genes in a neuroblastoma cell line. FASEB J. 2008 Mar;22(3):662-70. doi: 10.1096/fj.07-8346com. Epub 2007 Oct 12.
52 Mineralocorticoid receptor function in posttraumatic stress disorder after pretreatment with metyrapone. Biol Psychiatry. 2006 Oct 1;60(7):784-7. doi: 10.1016/j.biopsych.2006.01.014. Epub 2006 Mar 29.
53 Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer. 2012 Nov 1;118(21):5302-9. doi: 10.1002/cncr.27450. Epub 2012 Apr 4.
54 Suppression of spermatogenesis in patients with Beh?et's disease treated with cyclophosphamide and colchicine. Fertil Steril. 1981 Jul;36(1):76-80. doi: 10.1016/s0015-0282(16)45622-0.
55 [Kuntai capsule combined with gonadotropin releasing hormone agonist in treatment of moderate-severe endometriosis: a clinical observation]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2014 Nov;34(11):1288-91.
56 Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
57 Pharmacokinetics of new testosterone transdermal therapeutic systems in gonadotropin-releasing hormone antagonist-suppressed normal men. Exp Clin Endocrinol Diabetes. 1999;107(1):63-9. doi: 10.1055/s-0029-1212075.
58 Aromatase inhibition, testosterone, and seizures. Epilepsy Behav. 2004 Apr;5(2):260-3. doi: 10.1016/j.yebeh.2003.12.001.
59 Male sexual dysfunction during treatment with cimetidine. Br Med J. 1979 Mar 10;1(6164):659. doi: 10.1136/bmj.1.6164.659.
60 Effect of risperidone and olanzapine on reproductive hormones, psychopathology and sexual functioning in male patients with schizophrenia. Psychoneuroendocrinology. 2009 Jan;34(1):129-39. doi: 10.1016/j.psyneuen.2008.08.015. Epub 2008 Oct 5.
61 Estrogens exert route- and dose-dependent effects on insulin-like growth factor (IGF)-binding protein-3 and the acid-labile subunit of the IGF ternary complex. J Clin Endocrinol Metab. 2000 May;85(5):1918-22. doi: 10.1210/jcem.85.5.6527.
62 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
63 Erectile function and nocturnal penile tumescence in patients with prostate cancer undergoing luteinizing hormone-releasing hormone agonist therapy. Int J Urol. 1999 Jan;6(1):19-23. doi: 10.1046/j.1442-2042.1999.06128.x.
64 Relative progestational and androgenic activity of four progestins used for male hormonal contraception assessed in vitro in relation to their ability to suppress LH secretion in the castrate male rat. Mol Cell Endocrinol. 2010 Oct 26;328(1-2):16-21. doi: 10.1016/j.mce.2010.06.010. Epub 2010 Jun 25.
65 Chronic senescent human mesenchymal stem cells as possible contributor to the wound healing disorder after exposure to the alkylating agent sulfur mustard. Arch Toxicol. 2021 Feb;95(2):727-747. doi: 10.1007/s00204-020-02946-5. Epub 2021 Jan 25.
66 Differences in the opioid control of luteinizing hormone secretion between pathological and iatrogenic hyperprolactinemic states. J Clin Endocrinol Metab. 1987 Mar;64(3):508-12. doi: 10.1210/jcem-64-3-508.
67 The effect of alprazolam on serum cortisol and luteinizing hormone pulsatility in normal women and in women with stress-related anovulation. J Clin Endocrinol Metab. 1995 Mar;80(3):818-23. doi: 10.1210/jcem.80.3.7883836.
68 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.